Physician profile
Deepa Sirsi
NPI 1750548590
$2,773.43
in general payments reported to CMS, 2019-2025
7 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 75% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,000 · 2021: $37.30 · 2022: $36.96 · 2023: $130 · 2024: $49.14 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,200 · Travel and Lodging: $281 · Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,200.00 |
| Travel and Lodging | $280.97 |
| Food and Beverage | $218.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,212.51 | 2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Zogenix INC. | $1,000.00 | 2020 | |
| Neuropace, INC. | $280.97 | 2025 | |
| Ucb, INC. | $206.86 | 2021-2024 | Fintepla, Briviact |
| Neurelis, INC. | $46.56 | 2021-2024 | Valtoco |
| Upsher-Smith Laboratories LLC | $26.53 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Sirsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.